Abstract
BackgroundMelatonin, a well-known antioxidant, has been shown to possess anti-invasive properties for glioma. However, little is known about the effect of melatonin on glioma cell migration and invasion under hypoxia, which is a crucial microenvironment for tumor progress. In addition, focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) are closely associated with cell migration and invasion. Therefore, we investigated the possible role of these kinases and its related signaling in the regulation of human U251 glioma cells behavior by melatonin under hypoxia.MethodsThe abilities of migration and invasion of U251 glioma cells were determined by wound healing and transwell assay in vitro. The intracellular production of reactive oxygen species (ROS) was measured by using the fluorescent probe 6-carboxy-2′, 7′-dichorodihydrofluorescein diacetate (DCFH-DA). Immunofluorescence experiments and western blotting analysis were used to detect the expression level of protein. Small interfering RNAs (siRNA) was used to silence specific gene expression.ResultsThe pharmacologic concentration (1 mM) of melatonin significantly inhibited the migration and invasion of human U251 glioma cells under hypoxia. The inhibitory effect of melatonin was accompanied with the reduced phosphorylation of FAK and Pyk2, and decreased expression of alpha v beta 3 (αvβ3) integrin. Additionally, inhibition of αvβ3 integrin by siRNA reduced the phosphorylation of FAK/Pyk2 and demonstrated the similar anti-tumor effects as melatonin, suggesting the involvement of αvβ3 integrin- FAK/Pyk2 pathway in the anti-migratory and anti-invasive effect of melatonin. It was also found that melatonin treatment decreased the ROS levels in U251 glioma cells cultured under hypoxia. ROS inhibitor apocynin not only inhibited αvβ3 integrin expression and the phosphorylation levels of FAK and Pyk2, but also suppressed the migratory and invasive capacity of U251 glioma cells under hypoxia.ConclusionsThese results suggest that melatonin exerts anti-migratory and anti-invasive effects on glioma cells in response to hypoxia via ROS-αvβ3 integrin-FAK/Pyk2 signaling pathways. This provides evidence that melatonin may be a potential therapeutic molecule targeting the hypoxic microenvironment of glioma.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-015-0454-8) contains supplementary material, which is available to authorized users.
Highlights
Melatonin, a well-known antioxidant, has been shown to possess anti-invasive properties for glioma
Millimolar concentrations of melatonin displayed the ability to inhibit glioma cell migration and invasion through the inhibition of the oxidative stress pathway [1,2]. The majority of those studies were performed under normoxia, and little was done to observe the effect of melatonin on glioma under hypoxia, which results in the change of intracellular reactive oxygen species (ROS) status and is a crucial microenvironment for tumor progress
Compared with cells cultured under normoxia, many more U251 glioma cells migrated into the wound area under hypoxia in the wound healing assay, and simultaneous exposure to 1 mM melatonin significantly reduced hypoxia-induced U251 glioma cell migration (Figure 1A)
Summary
A well-known antioxidant, has been shown to possess anti-invasive properties for glioma. Little is known about the effect of melatonin on glioma cell migration and invasion under hypoxia, which is a crucial microenvironment for tumor progress. N-acetyl-5-methoxytryptamine, secreted predominately by the pineal gland, has antitumor properties on a variety of cancer types including glioma [1,2,3]. Millimolar concentrations of this indolamine were found to reduce U251 glioma cell growth by 70% after 72 hours of treatment, and intraperitoneal administration of melatonin (15 mg/kg body weight) to a rat subcutaneous U251 glioma model reduced tumor growth by 50% [4]. The majority of those studies were performed under normoxia, and little was done to observe the effect of melatonin on glioma under hypoxia, which results in the change of intracellular reactive oxygen species (ROS) status and is a crucial microenvironment for tumor progress
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.